Academic researchers, by nature, pursue scientifically interesting discoveries that could have a long-term impact. Meanwhile, investors and companies are interested in technologies that fill a very clear and immediate need in a market. That difference in perspective is one thing that makes translating discoveries at academic institutions into viable products so challenging, as I learned […]
Noninvasive cardiac mapping company CardioInsight Technologies said its CEO and Chairman Steve Arless is stepping down. No reason was given for Arless’ departure in a statement from the Cleveland-based company, which is fresh off a $7.5 million series C investment. “The board of directors expresses its appreciation for Mr. Arless’ service to the company during […]
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
Noninvasive cardiac mapping company CardioInsight Technologies has raised a $7.5 million series C round of investment. CardioInsight will use the new funding to push forward on European commercialization efforts and clinical studies aimed at obtaining U.S. regulatory clearance, according to a statement from the Cleveland-based company. MedCity News reported today that CardioInsight is in discussions […]
Cardiac mapping company CardioInsight Technologies is turning some of its attention toward the U.S. market after its first-ever product installation last month in the United Kingdom. But the Cleveland-based company will have to complete several key steps before U.S. commercialization can happen, CEO Steve Arless said. Company officials are in discussions with the U.S. Food […]
Fresh off the first-ever regulatory approval of one of its products, cardiac mapping company CardioInsight Technologies is on the fundraising trail. The Cleveland-based company recently filed regulatory documents, with one indicating it’s raised $1.6 million in convertible debt from 14 investors since May. Another filing shows that the company has raised $7.5 million in equity […]
Noninvasive cardiac imaging company CardioInsight Technologies has added another $1 million ahead of an August product launch in Europe. The Cleveland-based developer of new innovative medical devices was awarded a $1 million loan from the state of Ohio that it will use to help commercialize its technology. CardioInsight expects to receive European regulatory clearance in […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
CardioInsight Technologies has secured a Japanese distribution partner for its heart-mapping technology, and added about $4 million in investment funding that it hadn't previously disclosed.
Ohio Third Frontier commissioners made a slew of biomedical grants under two programs today. Recommended for more than $4.9 million under the Ohio Third Frontier Biomedical Program: — CardioX Corp., Dublin, in collaboration with Nottingham-Spirk Design Associates in Cleveland and QTest Labs in Columbus, was awarded $986,373 to finalize designs and clinical protocols for a […]
Steve Arless learned the hard way that it’s never too early to start talking to potential commercial partners that could help develop your early stage medical technology company. Arless told an Ohio Venture Association group on Friday that his decision to pass on an early commercial development offer ended up costing his company a lot […]
CardioInsight Technologies has closed its second funding round, raising $6 million from new and existing investors to speed up and expand testing and commercialization of its heart-mapping technology.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
CardioInsight Technologies Inc. has raised $5.7 million in an ongoing funding round to help commercialize its heart-mapping technology. The Cleveland company's electrocardiographic mapping technology could help diagnose and treat electrical abnormalities of the heart, such as heart failure and arrhythmia.